Document Detail

Olmesartan, an angiotensin II receptor blocker, restores cerebral hypoperfusion in elderly patients with hypertension.
MedLine Citation:
PMID:  20434053     Owner:  NLM     Status:  MEDLINE    
We evaluated the effects of olmesartan, an angiotensin II receptor blocker (ARB), on cerebral blood flow (CBF) in elderly and hypertensive subjects. Ten subjects with first- or second-degree essential hypertension (mean age, 70.5 years) underwent brain single-photon emission tomography (SPECT) scanning with (99m)Tc-ethyl cysteinate dimer before and after a 24-week course of olmesartan. Mean systolic blood pressure (SBP) was 156.2+/-9.9 mm Hg, and mean diastolic blood pressure (DBP) was 89.1+/-5.5mm Hg. No subject had any abnormalities on neurologic examination or previous history of stroke or cardiovascular disease. Before olmesartan administration, the hypertensive subjects had approximately 15% less whole brain CBF compared with age-matched normotensive controls. Regional CBF was decreased by 11%-20% in the frontal, parietal, temporal, and posterior lobes. Olmesartan treatment significantly decreased SBP to 130.4+/-4.2mm Hg (P < .001) and DBP to 78.2+/-7.0mm Hg (P < .001). After 24 weeks of olmesartan treatment, CBF of whole brain and regional CBF of the frontal, parietal, and temporal lobe were similar to those of control subjects. Our brain SPECT data indicate that olmesartan restores brain hypoperfusion in elderly and hypertensive patients without organic damage. This ARB may have a favorable potential for cerebrovascular circulation, in addition to a blood pressure-lowering effect.
Riya Nagata; Kiyokazu Kawabe; Ken Ikeda
Related Documents :
7880873 - Hypertension in the elderly population: prevalence data from an urban area in sweden.
2698943 - Antihypertensive efficacy and influence on physical activity of three different treatme...
7103023 - Anaesthesia and intra-ocular pressure: a comparative of total intravenous anaesthesia u...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association     Volume:  19     ISSN:  1532-8511     ISO Abbreviation:  J Stroke Cerebrovasc Dis     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-03     Completed Date:  2010-07-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111633     Medline TA:  J Stroke Cerebrovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  236-40     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Department of Neurology, Toho University Omori Medical Center, Tokyo 143-8541, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers / adverse effects,  therapeutic use*
Antihypertensive Agents / therapeutic use*
Blood Pressure / physiology
Brain / pathology
Cerebrovascular Circulation / drug effects*
Cysteine / analogs & derivatives,  therapeutic use
Hypertension / drug therapy*,  physiopathology
Imidazoles / adverse effects,  therapeutic use*
Magnetic Resonance Imaging
Organotechnetium Compounds / therapeutic use
Tetrazoles / adverse effects,  therapeutic use*
Tomography, Emission-Computed, Single-Photon
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Imidazoles; 0/Organotechnetium Compounds; 0/Tetrazoles; 0/olmesartan; 0/technetium Tc 99m bicisate; 52-90-4/Cysteine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Determinants of white matter hyperintensity volume in patients with acute ischemic stroke.
Next Document:  Indirect reperfusion in the setting of symptomatic carotid occlusion by treatment of bilateral verte...